Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease

• Autors principals: Charlotte Lichnog (Autor), Sha Klabunde (Autor), Emily Becker (Autor), Franklin Fuh (Autor), Philipp Tripal (Autor), Raja Atreya (Autor), Entcho Klenske (Autor), Rich Erickson (Autor), Henry Chiu (Autor), Chae Reed (Autor), Shan Chung (Autor), Clemens Neufert (Autor), Imke Atreya (Autor), Jacqueline McBride (Autor), Markus F. Neurath (Autor), Sebastian Zundler (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2019-02-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Background: Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in several phase III trials....